Development asset linked to Y-mAbs Therapeutics in public FDA and regional records.
pharma
Y-mAbs Therapeutics
Y-Mabs Therapeutics A/S
Y-mAbs Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
2015 Founded
68 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2015
- Employees
- 68
- Programs
- 1
- Drugs
- 5
- Patents
- 0
Y-mAbs Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Y-mAbs Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Y-mAbs Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
sargramostim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte-macrophage colony-stimulating factor receptor.
- Target
- Granulocyte-macrophage colony-stimulating factor receptor
- Mechanism
- Granulocyte-macrophage colony-stimulating factor receptor agonist
-
Development asset linked to Y-mAbs Therapeutics in public FDA and regional records.